

Drug Evaluated at CRDAC Meeting	Committee Members voting	Yes votes	No votes	Abstain	Number of speakers	FCOI positive testimony	Number with FCOI	FCOI negative testimony	FCOI neutral testimony	Percent of positive speakers with FCOI	Voting outcome: Approval, Disapproval, Tabled	Limited efficacy but positive support?
FDA-approved gadolinium-based contrast agents used with magnetic resonance imaging (MRI) scans: December 8, 2009	No formal vote				6	1	2	0	1	50	Approved	
Prasugrel: February 3, 2009	9	9	0	0	2	0	1	0	1	0	Approval (consensus)	NA
Telmisartan: July 29, 2009	7	0 (for unrestricted approval) 5 (for use in place if pt can't tolerate ramipril)	7 (for unrestricted) 2(for use as alternate to ramipril)	0	1	1	1	0	0	100	Approval (restricted use)	Yes
dronedarone 400 milligrams oral tablets: March 18, 2009	13	10	3	0	3	1	1	0	0	100	Approval (recommending narrowed scope and black box warning for class III-IV heart failure)	Limited efficacy on all cause mortality, dose and regimen need further study- but drug was effective at preventing hospitalization driven by a fibr/flutter
rivaroxaban oral tablets (10 milligrams): March 19, 2009	17	15	2	0	1	0	0	0	0	NA	Approval for 10mg dose, disapproval for lower dosage	NA
ticagrelor tablets, 90 milligrams: July 28, 2010	8	7	1	0	2	0	0	0	0	NA	Approval	NA
Revatio (sildenafil): July 29, 2010	13	7 (pending further info)	6	0	2	0	1	1	0	0	Tabled	No (limited efficacy but no positive support)
ARANESP (darbopoetin alfa): October 18, 2010	17	1	15	1	14	1	3	1	1	33.33	Disapproved (in this instance meaning committee disapproved withdrawing it from market)	No (limited efficacy but no positive support)
Ultrasound contrast agents: May 2, 2011	No formal vote				3	0	0	0	0	NA	Tabled	NA
NORTHERA (droxidopa capsules) 2012 Meeting: February 23, 2012	13	7	4 (and 1 no vote)	1	10	6	6	0	0	100	Approval with a post approval trial necessitated, results presented at 2014 meeting	Yes- initially approved with very limited scope
Lixivaptan: September 13, 2012	8	0 (for hypervolemic hyponatremia associated with heart failure) 3 (euvolemic hyponatremia associated with SIADH)	8 (hypervolemic hyponatremia associated with heart failure) 5 (euvolemic hyponatremia associated with SIADH)	0	2	2	2	0	0	100	Disapproved	*Yes*
tolvaptan tablets: August 5, 2013	15	6	9	0	10	1	1	0	0	100	Disapproved	NA
ADEMPAS (riociguat coated tablet): August 6, 2013	11	11	0	0	2	0	0	0	0	NA	Approval	NA
cangrelor injection Feb. 12, 2014	9	0	9	0	2	0	0	0	0	NA	Disapproved (need further studies)	NA
NORTHERA (droxidopa capsules) January 14, 2014	17	16	1	0	18	13	13	0	0	100	Approval	*Yes*
Serelaxin: March 27, 2014	11	0	11	0	2	0	0	0	0	NA	Disapproved	No
nebivolol/valsartan fixed dose combination tablets (5/80 milligrams (mg), 5/160 mg, 10/160 mg, 10/320 mg and 20/320 mg) September 9, 2014	10	4	6	0	1	0	0	0	0	NA	Disapproved	No
fixed-combination prescription drugs composed of an anti-hypertensive drug, aspirin, and a statin September 10, 2014	No formal vote				3	2	2	0	0	100	Approved (consensus)	
cangrelor injection 2015 Meeting	12	9	2	1	2	1	1	0	0	100	Approved	No
Vernakalant hydrochloride solution December 10, 2019	13	2	11	0	2	1	1	0	0	100	Disapproved	No
TOTAL					88	30	35	2	3			